Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder
Key facts
- Who runs it
- New York State Psychiatric Institute
- Where
- New York, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1/2
- Started
- 1 Mar 2022
- Ended
- 8 May 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Nabilone
- Placebo
- Record updated
- 21 May 2024
- Why it stopped
- The Principal Investigator is no longer at the Institution and a request for early termination of the grant supporting the study was submitted to NIH.
Who can take part
- Age
- 21 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Between 21-55 years of age
- Physically healthy and, if female, not pregnant
- Able to tolerate all study procedures
- Able to provide written informed consent to participate
- Right-handed
- Primary diagnosis of OCD
- Not taking psychotropic medications or other substances likely to interact with nabilone
Who cannot take part
- History of receiving cognitive behavior or exposure-based psychotherapy in the past 3 months
- History of any significant medical condition that may increase the risk of participation
- Current or lifetime history of psychiatric disorders other than OCD that may increase the risk of participation (e.g. lifetime psychosis or bipolar disorder)
- Current substance use disorder
- Any history of adverse reaction to a cannabinoid
- History of ferrous-containing metals within the body (e.g., aneurysm clips, shrapnel/retained particles)
- History of claustrophobia or unable to tolerate confined spaces like an MRI
- Females who are pregnant or nursing
- Positive urine toxicology or alcohol breathalyzer
Where in United States
- New York State Psychiatric InstituteNew York, United States
About the trial
What the trial wants to find out
The purpose of this research study is to test how a medication called nabilone (Cesamet) affects neurocognitive processes involved in obsessive-compulsive disorder (OCD), including threat response, processing of fear signals, and habitual behavior. OCD is a disabling illness that affects around 2% of the population and involves recurrent intrusive thoughts (obsessions) and repetitive behaviors (compulsions) that lead to distress and/or impaired functioning. Nabilone is a synthetic form of delta-9-tetrahydrocannabinol (THC, the primary psychoactive component of the cannabis plant). It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD symptoms. Nabilone is approved by the FDA for the treatment of chemotherapy-induced nausea and vomiting. It is not FDA-approved for treating OCD.
Read full original descriptionShow less
In this study, 60 adults with OCD will receive a single dose of either nabilone or placebo. Participants will then complete a series of assessments including neuroimaging, psychophysiology (e.g., skin conductance recording), computerized behavioral tasks, and self-report measures. The information gained from this study could contribute to the development of new treatments for people with OCD and related disorders.
The 2 groups in the trial
- NabiloneExisting treatment, for comparison
In a randomized, double-blind, placebo-controlled design, we will administer a one-time oral dose of nabilone (1mg) or placebo approximately two hours prior to fMRI scanning and task performance in 60 adults with OCD.
- PlaceboPlacebo, for comparison
In a randomized, double-blind, placebo-controlled design, we will administer a one-time oral dose of nabilone (1mg) or placebo approximately two hours prior to fMRI scanning and task performance in 60 adults with OCD.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 21 May 2024